Chemistry & Biology Brief Communication



Cloning, Expression, and Biochemical Characterization of *Streptomyces rubellomurinus* Genes Required for Biosynthesis of Antimalarial Compound FR900098

Andrew C. Eliot,^{1,5} Benjamin M. Griffin,² Paul M. Thomas,^{2,3} Tyler W. Johannes,^{2,4} Neil L. Kelleher,^{2,3} Huimin Zhao,^{2,4} and William W. Metcalf^{1,2,*}

¹Department of Microbiology, University of Illinois, 601 South Goodwin Avenue, Urbana, IL 61801, USA

²Institute for Genomic Biology, University of Illinois, 1206 West Gregory, Urbana, IL 61801, USA

³Department of Chemistry

⁴Department of Chemical and Biomolecular Engineering

University of Illinois at Urbana-Champaign, 600 South Matthews Avenue, Urbana, IL 61801, USA

⁵Present address: DuPont Central Research and Development, Experimental Station E328/250A, Wilmington, DE 19880, USA

*Correspondence: metcalf@uiuc.edu

DOI 10.1016/j.chembiol.2008.07.010

SUMMARY

The antibiotics fosmidomycin and FR900098 are members of a unique class of phosphonic acid natural products that inhibit the nonmevalonate pathway for isoprenoid biosynthesis. Both are potent antibacterial and antimalarial compounds, but despite their efficacy, little is known regarding their biosynthesis. Here we report the identification of the Streptomyces rubellomurinus genes required for the biosynthesis of FR900098. Expression of these genes in Streptomyces lividans results in production of FR900098, demonstrating their role in synthesis of the antibiotic. Analysis of the putative gene products suggests that FR900098 is synthesized by metabolic reactions analogous to portions of the tricarboxylic acid cycle. These data greatly expand our knowledge of phosphonate biosynthesis and enable efforts to overproduce this highly useful therapeutic agent.

INTRODUCTION

Afflicting an estimated 500 million people and causing over 1 million deaths per year, malaria exacts a terrible toll in tropical and subtropical regions (Snow et al., 2005). Although a number of antimalarial treatments exist, resistance is increasingly common, creating an urgent need for new drugs (Schlitzer, 2007). Among the most promising of such new antimalarial therapies are the phosphonic acid antibiotics FR900098 and fosmidomycin (Figure 1A).

These two compounds were originally identified as antibiotics produced by *Streptomyces rubellomurinus* and *Streptomyces lavendulae*, respectively (Okuhara et al., 1980). Subsequent studies showed that both act as potent inhibitors of 1-deoxy-Dxylulose 5-phosphate reductoisomerase (DXR), the first enzyme in the nonmevalonate pathway for isoprenoid biosynthesis (Kuzuyama et al., 1998; Rohmer, 1999). The identification of this pathway in the malaria-causing parasite *Plasmodium falciparum* renewed interest in these phosphonate antibiotics as potential antimalarial drugs (Jomaa et al., 1999). Both FR900098 and fosmidomycin are effective against *P. falciparum* in vitro and against the closely related *P. vinckei* in mice (Jomaa et al., 1999). These drugs are active even against multidrug-resistant strains of *P. falciparum* (Jomaa et al., 1999).

Given the importance of this new class of antimalarial compounds, we aimed to identify the FR900098 biosynthetic genes from S. rubellomurinus. To date, complete biosynthetic gene clusters have been identified for only three phosphonate compounds: aminoethylphosphonate (Barry et al., 1988), fosfomycin (Hidaka et al., 1995), and bialaphos (Blodgett et al., 2005; Schwartz et al., 2004). These and other studies led to the proposal that the initial step in all phosphonate biosyntheses is the rearrangement of phosphoenolpyruvate (PEP) to form phosphonopyruvate, catalyzed by the enzyme PEP mutase (Seidel et al., 1988; Figure 1B). Consistent with this idea, PEP mutase activity was detected in cell-free extracts of S. rubellomurinus (Hidaka et al., 1989). We therefore developed a PEP mutase gene-targeted approach to identify the FR900098 biosynthetic genes, which is reported here along with heterologous expression and production of the antibiotic in S. lividans. These results provide significant new insight into the biosynthesis of phosphonic acid antibiotics and make possible efforts to enhance bioproduction of this important antimalarial compound.

RESULTS AND DISCUSSION

A PCR-based strategy was used to clone the FR900098 biosynthetic gene cluster. Based on the precedent of other phosphonate biosyntheses, we assumed that the initial step in FR900098 biosynthesis is the PEP mutase-catalyzed rearrangement to form phosphonopyruvate. Using degenerate primers designed to anneal to conserved sequences within known PEP mutase genes (Blodgett et al., 2005), we were able to amplify a 406 bp fragment from *S. rubellomurinus* genomic DNA that encodes a peptide homologous to known PEP mutases. On the assumption that the biosynthetic genes for FR900098 are clustered on the chromosome, we constructed a large insert fosmid library from *S. rubellomurinus* genomic DNA. PCR screening of the




Figure 1. Phosphonic Acid Antibiotics and Their Biosynthesis

(A) The structures of the antimalarial compounds FR900098 and fosmidomycin. Both inhibit DXR, an essential enzyme in the isoprenoid biosynthetic pathway in malaria-causing parasites.

(B) The initial reactions in the biosynthesis of 2-aminoethylphosphonic acid, fosfomycin, and bialaphos. In the first step, catalyzed by PEP mutase, phosphoenolpyruvate is rearranged to phosphonopyruvate, which is then decarboxylated to yield phosphonoacetaldehyde in a reaction catalyzed by phosphonopyruvate decarboxylase.

library using PEP mutase-specific primers allowed identification of four clones encoding the putative PEP mutase. We transferred one of these clones (designated 4G7) to the chromosome of *Streptomyces lividans*, a genetically tractable organism that is not known to produce phosphonic acid compounds, in an attempt to determine if fosmid 4G7 contained all the genes necessary for production of FR900098. Production of FR900098 by the recombinant *S. lividans* strain was confirmed by four lines of evidence (Figure 2).

First, supernatant from cultures of *S. lividans* 4G7 inhibited purified *E. coli* DXR. This enzyme is the known target of the antibiotic (Kuzuyama et al., 1998) and can be completely inhibited by concentrations of FR900098 as low as 100 nM (data not shown). Supernatant from cultures of *S. lividans* 4G7 eliminated DXR activity, whereas supernatant from cultures of the parent *S. lividans* strain grown under the same conditions had no effect (Figure 2A).

Second, we developed a two-plate assay system utilizing an engineered *E. coli* bioassay strain (see Supplemental Data available online) with an IPTG-inducible hypersensitivity to phosphonate antibiotics. In the presence of inducer, both authentic FR900098 (50 μ g/ml) and supernatant from *S. lividans* 4G7 produced substantial zones of inhibition, whereas the parent *S. lividans* strain did not (Figure 2B).

Third, ³¹P-NMR spectroscopy of concentrated *S. lividans* 4G7 culture supernatant revealed a signal at ~25 ppm that was intensified when authentic FR900098 was added to the sample. No new signal was observed, indicating that the phosphonate species in the supernatant is FR900098 or a closely related compound (Figure 2C). No peaks are observed in this region of the

spectrum in supernatant from cultures of the *S. lividans* parent strain.

Fourth, the presence of FR900098 in the *S. lividans* 4G7 culture supernatant was further confirmed by coupled liquid chromatography high-resolution mass spectrometry (LCMS) (Figure 2D). In addition to FR900098, we detected *N*-acetyl-3aminophosphonate, suggesting that this compound may be an intermediate in the synthesis of the antibiotic (Figure S1).


Fosmid 4G7 was sequenced using a transposon-based strategy as described in the Supplemental Data. The mini-MuAE5 transposon used in this effort also allowed facile construction of deletion subclones lacking the region between the site of transposon insertion and the cloning junction with the fosmid vector. We tested a series of progressively larger deletion plasmids for their ability to confer FR900098 production upon *S. lividans*, resulting in the identification of a minimal 11.3 kb region required for antibiotic synthesis (Figure 3A).

Analysis of the minimal DNA sequence revealed eight open reading frames (ORFs), which were designated *frbA-H* for <u>ER900098 b</u>iosynthesis, including the expected PEP mutase homolog (*frbD*). In addition, two ORFs (designated *frbI* and *frbJ*) immediately downstream of *frbH* appear to be part of the same operon, although they are not required for successful antibiotic production in *S. lividans*. Downstream of *frbJ* and separated from it by a region containing a 38 bp inverted repeat is an ORF that is homologous to the gene for DXR. We have designated this ORF *dxrB*. Possible functions of the Frb proteins were assigned based on homology to proteins of known function (Table S1).

The initial step in FR900098 biosynthesis is presumed to be the PEP mutase-catalyzed formation of phosphonopyruvate, a highly unfavorable reaction (equilibrium is \geq 500:1 in favor of PEP) (Bowman et al., 1990). In known phosphonate biosynthetic pathways, the second step is an irreversible decarboxylation of phosphonopyruvate, which provides a thermodynamic driving force to overcome the unfavorable initial step (Figure 1B). Surprisingly, there is no recognizable homolog of phosphonopyruvate decarboxylase in the FR900098 gene cluster. A clue to the fate of phosphonopyruvate is suggested by the presence of three putative ORFs (frbA, frbB, and frbE; Table S1 and Figure 3A) that are related to genes encoding enzymes in the TCA cycle. A fourth (frbC) is homologous to homocitrate synthase, which catalyzes an acetyl-CoA condensation similar to that catalyzed by citrate synthase. Considering that phosphonopyruvate is a structural analog of oxaloacetate, we proposed that the initial steps in biosynthesis of FR900098 parallel the TCA cycle (Figure 3B). Thus, the thermodynamically favorable reactions catalyzed by the homocitrate synthase and isocitrate dehydrogenase homologs would provide the necessary thermodynamic driving force. Hemmi et al. (1982) have previously suggested that such a pathway would be feasible, and there is a precedent in the bialaphos biosynthetic pathway in which phosphinopyruvate is converted to the phosphinic acid analog of a-ketoglutarate (αKG) by an analogous series of reactions (reviewed by Seto and Kuzuyama, 1999).

To test the prediction that *frbC* and *frbD* encode phosphonomethylmalate synthase and PEP mutase, respectively, recombinant FrbC and FrbD were purified and assayed. Using an in vitro assay based on a method commonly used to assay citrate








Figure 2. Evidence for the Heterologous Production of FR900098

(A) Detection of FR900098 by enzymatic assay. Culture supernatant from the nonproducing S. *lividans* parent strain (\bigcirc) does not affect the reaction catalyzed by *E. coli* DXR, as measured by observing the decrease in absorbance at 340 nm that results from oxidation of NADPH during the reaction. Culture supernatant from *S. lividans* 4G7 (\bigcirc) results in complete inhibition. The initial absorbance has been normalized to 1 for both reactions for ease of comparison.

(B) Detection of FR900098 by a phosphonate-specific bioassay. The phosphonate-sensitive *E. coli* indicator strain WM6242 was assayed either uninduced (top) or induced (bottom) allowing for detection of phosphonate-containing antibiotics. Disks labeled 1 were soaked with authentic FR900098 (50 μ g/ml). Disks labeled 2 were soaked with supernatant from S. *lividans* 4G7. Disks labeled 3 were soaked with supernatant from the parent S. *lividans* strain without a cosmid.

(C) ³¹P-NMR spectra of commercial FR900098 (left), culture supernatant from S. *lividans* 4G7 (center), and the same culture supernatant after addition of commercial FR900098 (right).

(D) Selected ion chromatogram for FR900098 \pm 2 ppm from an injection of culture supernatant with summed mass spectrum (inset).

The identity of the enzyme responsible for the subsequent hydroxylation reaction is less clear. FrbJ is homologous to α KG-dependent dioxygenases, a class of enzymes that may be capable of *N*-hydroxylation, but catalysis of that type of

synthase, we observed CoASH formation from acetyl-CoA and phosphonopyruvate in the presence of FrbC (Figure 4A), suggesting that FrbC catalyzes condensation of the two molecules driven by CoA thioester hydrolysis. We could further detect CoASH formation starting from PEP and acetyl-CoA if both FrbC and FrbD were present, confirming that FrbD is a PEP mutase. ³¹P-NMR analysis of the reaction products revealed the presence of a new phosphonic acid (data not shown), which was confirmed to be 2-phosphonomethylmalate by LCMS (Figure 4B).

The product of the three TCA cycle analog reactions, 2-oxo-4phosphonobutyrate, would be a phosphonate analog of α KG, which could be converted into 3-aminopropylphosphonate by consecutive amination and decarboxylation reactions. FrbH is a homolog of PLP-dependent enzymes that are known to catalyze both reaction types (e.g., histidinol phosphate aminotransferase and threonine phosphate decarboxylase) and could be involved in either reaction.

To complete the biosynthesis of FR900098, the amino group of 3-aminopropylphosphonate would need to be both acetylated and hydroxylated. Because we detect *N*-acetyl-3-aminophosphonate and not *N*-hydroxy-3-aminophosphonate by LCMS of the heterologous producer, we suggest the order is acetylation followed by hydroxylation. FrbF shows high identity to *N*-acetyltransferases and likely performs that reaction here.

reaction by an enzyme of this class is without precedent. We propose no role for FrbG, which shows only very weak homology to the small subunit of glutamate synthase. More definitive assignment of the function of these enzymes will have to await in vitro biochemical and in vivo genetic experiments.

Although *dxrB* is not required for production of FR900098, its presence near the biosynthetic genes suggests a role in self-resistance. The use of resistant forms of target enzymes has been observed in other organisms. For example, a cycloserine-producing *S. lavendulae* strain has been shown to also produce a cycloserine-resistant variant of alanine racemase, the target of that inhibitor (Noda et al., 2004). We are currently investigating whether the DXR encoded within the FR900098 cluster is indeed resistant to FR900098.

Because we propose a role for the *dxrB* gene in self-resistance, we have tentatively defined the FR900098 biosynthetic gene cluster as comprising the entire region from *frbA* to *dxrB*, although the *frbA-H* fragment alone is sufficient for production of FR900098 in *S. lividans*.

SIGNIFICANCE

Our data suggest that the pathway for biosynthesis of this antibiotic may have evolved from the tricarboxylic acid cycle of central metabolism and utilizes an unusual




Figure 3. The FR900098 Biosynthetic Gene Cluster

(A) The arrangement of the FR900098 biosynthetic genes. The end points of largest deletions that do not eliminate antibiotic production (Δ126 and Δ 191) and smallest deletions that do (Δ 061 and Δ 136) are also shown. Δ 126 ends 117 bp before the end of frbA, Δ191 removes 2233 of 2660 bp of frbA, Δ 136 removes 934 of 1886 bp of frbH, and Δ 191 removes 51 of 1886 bp of frbH. The reaion from frbA to frbH is sufficient for production of FR900098 in the heterologous host S. lividans. (B) The proposed biosynthetic pathway for FR900098. The assignment of ORFs to chemical steps is based on the proposed functions as deduced from sequence comparisons. Intermediates in the production of FR900098: I, phosphoenolpyruvate; II, 3-phosphonopyruvate; III, 2-phosphonomethylmalate: IV. 3-phosphonomethylmalate: V. 2-oxo-4-phosphonobutryate; VI, 2-amino-4-phosphonobutyrate; VII, 3-aminopropylphosphonate; VIII, N-hydroxy-3-aminopropylphosphonate; IX,

vidually recombined in vitro with pAE4 using BP clonase according to the manufacturer's instructions. Fosmid:pAE4 cointegrants were isolated after transformation of *E. coli* DH5 α and subsequently moved into the conjugal donor strain

N-acetyl-3-aminopropylphosphonate.

thermodynamic driving reaction distinct from other phosphonate biosynthetic pathways. Heterologous production of FR900098 is possible using the identified genes, allowing for creation of engineered strains that greatly overproduce the antibiotic. Our proposed FR900098 biosynthetic pathway includes two potent bioactive compounds as intermediates: 2-amino-4-phosphonobutyrate and 3-aminopropylphosponate, which are known mimics of the major neurotransmitters glutamate and γ -aminobutyrate, respectively (Jane, 2000). Thus in addition to the biosynthesis of the antimalarial compound FR900098, elucidation of this pathway in *S. rubellomurinus* has uncovered a biosynthetic route to these two well-known neuroactive compounds.

EXPERIMENTAL PROCEDURES

Cloning of the FR900098 Gene Cluster from S. rubellomurinus

S. rubellomurinus strain 5818 (ATCC 31215) was provided by the Fujisawa Pharmaceutical (Osaka, Japan). S. lividans 66 was obtained from the USDA Agricultural Research Service Culture Collection (Peoria, IL). See Supplemental Data for details on the strains and plasmids (Figure S2) used for cloning. The PEP mutase gene in S. rubellomurinus was identified by PCR amplification with degenerate primers (see Supplemental Data), which were designed using CODEHOP (Rose et al., 1998) based on known PEP mutase sequences. Specific primers were designed to the S. rubellomurinus PEP mutase gene based on the sequence of the amplification product. A genomic library of S. rubellomurinus was prepared using genomic DNA obtained by a modification of the method of Kieser et al. (2000) and is described in detail in the Supplemental Data. This genomic DNA was partially digested to yield fragments of ~20-60 kb, which were then ligated into pJK050. E. coli WM3118 cells were transfected with the resulting fosmids. The E. coli library was screened by PCR for clones containing the PEP mutase sequence. To add the functions necessary for transfer and integration into S. lividans, the purified fosmids were indiquently moved into the conjugal donor strain *E. coli* WM3608 (Blodgett et al., 2005) for transfer to *S. lividans* 66. Conjugal transfer was performed as described by Martinez et al. (2004) with modifications as detailed in the Supplemental Data.

Heterologous Expression of the FR900098 Gene Cluster in *S. lividans*

To check for production of FR900098, *S. lividans* 4G7 was plated on Hickey-Tresner agar (Kieser et al., 2000) or ISP4. After 4 days, the agar-solidified medium was liquefied by freezing and subsequent thawing, and the liquid portion was decanted from the remaining agar residue. To determine the presence or absence of FR900098 in this supernatant, 5 μ l was added to a DXR enzyme reaction, and the reaction rate was compared with a control with 5 μ l of supernatant from a nonproducing strain. Purified recombinant *E. coli* DXR used in the assays was prepared as described in the Supplemental Data.

The biosassay strain *E. coli* WM6242, which expresses the phosphonate uptake system encoded by *phnCDE* under the control of a P_{tac} promoter was constructed and used as described in Supplemental Data. Filter discs (6 mm) were impregnated with 9 μ l of the test solutions and placed on the surface of the solidified plates. The bioassay plates were incubated for 12 h, and the size of the growth inhibition zone scored. To confirm the heterologous production of FR900098, inhibition zones from *S. lividans* 4G7 culture supernatant were compared with supernatant from the *S. lividans* parent strain and a solution of authentic FR900098 (50 μ g/ml).

For ³¹P-NMR detection of FR900098, culture supernatant was concentrated approximately 10-fold by evaporation. ³¹P-NMR spectra were externally referenced to an 85% phosphoric acid standard set at 0 ppm. To confirm that the observed peak corresponded to FR900098, an authentic sample of FR900098 was added to a concentration of 100 μ g/mL, and the spectrum of the sample was recorded again under identical conditions. For the mass spectrometric detection of FR900098 and *N*-acetyl-3-aminophosphonate, samples were prepared, separated on an Atlantis HILIC silica column, and infused into a LTQ-FT mass spectrometer for negative ion FTMS detection as described in detail in Supplemental Data. The identities of FR900098 and *N*-acetyl-3-aminophosphonate were confirmed by both accurate mass analysis (<2 ppm) and tandem MS fragmentation.




Figure 4. Biochemical Evidence for 2-Phosphonomethylmalate as an Intermediate in the FR900098 Biosynthetic Pathway

(A) In vitro CoASH formation from acetyl-CoA and phosphonopyruvate or phosphoenolpyruvate depends on the presence of FrbC or FrbC + FrbD respectively.

(B) Selected ion chromatogram for 2-phosphonomethylmalate \pm 1 ppm from an injection of reaction mixture (20 μ L) with summed mass spectrum (inset). (C) High-resolution MS² spectrum for the precursor ion at negative *m*/*z* 227 showing the predictable losses of water and the added acetyl group.

DNA Sequencing and Deletion Analysis of Cosmid 4G7

To sequence fosmid 4G7, a library of transposon insertions was generated using the mini-Mu transposon encoded in pAE5 and sequenced as described in Supplemental Data. Potential open-reading frames were identified using BLAST analysis (Altschul et al., 1990), GeneMark (Borodovsky and McIninch, 1993), and visual inspection. To determine the portion of the cosmid required for antibiotic production, various deletions were made by site-specific recombination between frt or loxP sites present adjacent to the cloning site of the fosmid vector and the matching site on selected mini-Mu transposon insertions. These deletions remove all DNA between the site of the transposon insertion (chosen based on the DNA sequencing results) and the cloning junction in fosmid 4G7. The resulting recombinant plasmids were integrated into *S. lividans* 66, and exconjugants were assayed for the ability to produce FR900098 using the *E. coli* DXR inhibition assay and by mass spectrometry. The complete sequence of this 14.4 kb region has been deposited in GenBank with accession number DQ267750.

Determination of Enzymatic Activity of FrcB and FrbD

The *N*-His₆-tagged FrbC and FrbD proteins, purified after recombinant expression of genes, were obtained by PCR amplification from the fosmid 4G7 as described in Supplemental Data. Phosphonomethylmalate synthase activity was assayed by tracking CoASH formation in a reaction similar to that used for phosphinomethylmalate synthase (Shimotohno et al., 1988) starting from either phosphoenolpyruvate or phosphonopyruvate and using FrbD + FrbC or FrbC, respectively. Phosphonomethylmalate formation was confirmed using LCMS by both accurate mass analysis (<2 ppm) and tandem MS fragmentation (see Supplemental Data for a detailed description of the enzyme assay conditions and analytical methods).

ACCESSION NUMBERS

The complete sequence of this 14.4 kb region has been deposited in GenBank with accession number DQ267750.

SUPPLEMENTAL DATA

Supplemental Data include two figures, one table, Supplemental Experimental Procedures, and Supplemental References, and can be found with this article online at http://www.chembiol.com/cgi/content/full/15/8/765/DC1/.

ACKNOWLEDGMENTS

We thank the Fujisawa Company for providing *S. rubellomurinus* 5818, Adam Guss for constructing strain WM3118, and Jun Kai Zhang for constructing plasmid pJK050. We are also grateful to Deborah Dunaway-Mariano for providing phosphonopyruvate, and Chris Wright and Laura Guest of the UIUC Biotechnology Center for their help with sequencing. This work was supported by NIGMS Grants GM059334B to W.W.M., GM077596 to H.Z., and GM077596 to W.W.M., W.A.V., H.M.Z., and N.L.K.; U.S. National Institutes of Health Chemical Biology Interface Training Grant 5T32 GM070421; and a National Science Foundation postdoctoral fellowship to A.C.E. Support was also provided by the Institute for Genomic Biology Fellows Program (to B.M.G.).

Received: March 21, 2008 Revised: June 30, 2008 Accepted: July 8, 2008 Published: August 22, 2008

REFERENCES

Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local alignment search tool. J. Mol. Biol. 215, 403–410.

Barry, R.J., Bowman, E., McQueney, M., and Dunaway-Mariano, D. (1988). Elucidation of the 2-aminoethylphosphonate biosynthetic pathway in *Tetrahymena pyriformis*. Biochem. Biophys. Res. Commun. *153*, 177–182.

Blodgett, J.A., Zhang, J.K., and Metcalf, W.W. (2005). Molecular cloning, sequence analysis, and heterologous expression of the phosphinothricin tripeptide biosynthetic gene cluster from *Streptomyces viridochromogenes* DSM 40736. Antimicrob. Agents Chemother. *49*, 230–240.

Borodovsky, M., and McIninch, J. (1993). GeneMark: parallel gene recognition for both DNA strands. Comput. Chem. *17*, 123–133.

Bowman, E.D., McQueney, M.S., Scholten, J.D., and Dunaway-Mariano, D. (1990). Purification and characterization of the *Tetrahymena pyriformis* P-C bond forming enzyme phosphoenolpyruvate phosphomutase. Biochemistry *29*, 7059–7063.

Hemmi, K., Takeno, H., Hashimoto, M., and Kamiya, T. (1982). Studies on phosphonic acid antibiotics. IV. Synthesis and antibacterial activity of analogs of 3-(N-acetyl-N-hydroxyamino)-propylphosphonic acid (FR-900098). Chem. Pharm. Bull. (Tokyo) *30*, 111–118.

Hidaka, T., Goda, M., Kuzuyama, T., Takei, N., Hidaka, M., and Seto, H. (1995). Cloning and nucleotide sequence of fosfomycin biosynthetic genes of *Streptomyces wedmorensis*. Mol. Gen. Genet. *249*, 274–280.

Hidaka, T., Mori, M., Imai, S., Hara, O., Nagaoka, K., and Seto, H. (1989). Studies on the biosynthesis of bialaphos (SF-1293). 9. Biochemical mechanism of C-P bond formation in bialaphos: discovery of phosphoenolpyruvate phosphomutase which catalyzes the formation of phosphonopyruvate from phosphoenolpyruvate. J. Antibiot. (Tokyo) *42*, 491–494.

Jane, D.E. (2000). Neuroactive aminophosphonic and aminophosphinic acid derivatives. In Aminophosphonic and Aminophosphinic Acids, V.P. Kukjar and H.R. Hudson, eds. (New York: John Wiley & Sons), pp. 483–535.

Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C., Hintz, M., Turbachova, I., Eberl, M., Zeidler, J., Lichtenthaler, H.K., et al. (1999). Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science *285*, 1573–1576.

Kieser, T., Bibb, M.J., Buttner, M.J., Chater, K.F., and Hopwood, D.A. (2000). Practical *Streptomyces* Genetics (Norwich, UK: John Innes Foundation).

Kuzuyama, T., Shimizu, T., Takahashi, S., and Seto, H. (1998). Fosmidomycin, a specific inhibitor of 1-deoxy-d-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway for terpenoid biosynthesis. Tetrahedron. Lett. *39*, 7913–7916.

Martinez, A., Kolvek, S.J., Yip, C.L., Hopke, J., Brown, K.A., MacNeil, I.A., and Osburne, M.S. (2004). Genetically modified bacterial strains and novel bacterial artificial chromosome shuttle vectors for constructing environmental libraries and detecting heterologous natural products in multiple expression hosts. Appl. Environ. Microbiol. *70*, 2452–2463.

Noda, M., Kawahara, Y., Ichikawa, A., Matoba, Y., Matsuo, H., Lee, D.G., Kumagai, T., and Sugiyama, M. (2004). Self-protection mechanism in D-cycloserine-producing *Streptomyces lavendulae*. Gene cloning, characterization, and kinetics of its alanine racemase and D-alanyl-D-alanine ligase, which are target enzymes of D-cycloserine. J. Biol. Chem. *279*, 46143–46152. Okuhara, M., Kuroda, Y., Goto, T., Okamoto, M., Terano, H., Kohsaka, M., Aoki, H., and Imanaka, H. (1980). Studies on new phosphonic acid antibiotics. I. FR-900098, isolation and characterization. J. Antibiot. (Tokyo) *33*, 13–17.

Rohmer, M. (1999). The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. Nat. Prod. Rep. *16*, 565–574.

Rose, T.M., Schultz, E.R., Henikoff, J.G., Pietrokovski, S., McCallum, C.M., and Henikoff, S. (1998). Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences. Nucleic Acids Res. 26, 1628–1635.

Schlitzer, M. (2007). Malaria chemotherapeutics part 1: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem 2, 944–986.

Schwartz, D., Berger, S., Heinzelmann, E., Muschko, K., Welzel, K., and Wohlleben, W. (2004). Biosynthetic gene cluster of the herbicide phosphinothricin tripeptide from *Streptomyces viridochromogenes* Tu494. Appl. Environ. Microbiol. *70*, 7093–7102.

Seidel, H.M., Freeman, S., Seto, H., and Knowles, J.R. (1988). Phosphonate biosynthesis: isolation of the enzyme responsible for the formation of a carbon-phosphorus bond. Nature *335*, 457–458.

Seto, H., and Kuzuyama, T. (1999). Bioactive natural products with carbonphosphorus bonds and their biosynthesis. Nat. Prod. Rep. *16*, 589–596.

Shimotohno, K.W., Seto, H., Otake, N., Imai, S., and Murakami, T. (1988). Studies on the biosynthesis of bialaphos (Sf-1293). 8. Purification and characterization of 2-phosphinomethylmalic acid synthase from *Streptomyces Hygroscopicus* Sf-1293. J. Antibiot. (Tokyo) *41*, 1057–1065.

Snow, R.W., Guerra, C.A., Noor, A.M., Myint, H.Y., and Hay, S.I. (2005). The global distribution of clinical episodes of *Plasmodium falciparum* malaria. Nature *434*, 214–217.